Wilson Sonsini Goodrich & Rosati has advised PMV Pharmaceuticals. Brown Rudnick LLP has acted as intellectual property counsel for PMV Pharmaceuticals. Paul Hastings LLP has advised...
PMV Pharmaceuticals Announces $50.8 Million Public Offering
Humacyte Announces $50 Million Public Offering of Common Stock
Paul Hastings LLP has advised Barclays, BTIG and Titan Partners. Covington & Burling LLP has advised Humacyte, Inc. Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform...
Alvotech Announces $152 Million Public Offering and Concurrent Private Placement
Paul Hastings LLP has advised BofA Securities, Jefferies, and Evercore ISI. Cooley LLP has advised Alvotech. Alvotech has launched an aggregate public offering and concurrent private...
Kailera Therapeutics Completes Record $625 Million IPO
Paul Hastings LLP has advised J.P. Morgan Securities, Jefferies, Leerink, TD Cowen and Evercore. Latham & Watkins has advised Kailera Therapeutics. Kailera Therapeutics has successfully completed...
Forte Biosciences Announces $150 Million Public Offering of Common Stock
Wilson Sonsini Goodrich & Rosati has advised Forte Biosciences. Paul Hastings LLP has advised Guggenheim Securities and Barclays. Forte Biosciences, Inc., a clinical-stage biopharmaceutical company specializing...
Sol-Gel Technologies Completes $33.1 Million Underwritten Share Offering
Paul Hastings LLP and Gornitzky & Co. have advised TD Cowen and LifeSci Capital as joint bookrunning managers. Sol-Gel Technologies Ltd. (Nasdaq: SLGL), a specialized dermatology...
Stem Launches $30 Million At-the-Market Common Stock Offering
Gibson Dunn has advised Stem, Inc.; Paul Hastings has advised Jefferies LLC. Stem, Inc., a global leader in AI-enabled clean energy software and services, has launched...
Candel Therapeutics Completes $100 Million Public Offering and Secures Royalty Funding Agreement
Goodwin has advised Candel Therapeutics, Inc. Paul Hastings LLP has advised Citigroup, Cantor and Stifel as joint bookrunning managers. Candel Therapeutics, Inc. has completed an underwritten...
Compass Pathways Announces $150 Million Public Offering of American Depositary Shares
Paul Hastings LLP has advised Jefferies, TD Cowen, Cantor and Stifel as joint book-runners. Compass Pathways plc has announced the pricing of its public offering of...
Corvus Pharmaceuticals Completes US$201 Million Upsized Public Offering
Latham & Watkins LLP has advised Corvus Pharmaceuticals. Paul Hastings LLP has advised Jefferies and Goldman Sachs & Co. LLC. Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS) has...
Aktis Oncology Prices $317.7 Million Initial Public Offering
Paul Hastings LLP has advised Aktis Oncology on its upsized initial public offering. Aktis Oncology, a clinical?stage biotechnology company developing radiopharmaceuticals for cancer treatment, has successfully...
Vor Biopharma Announces $100 Million Public Offering of Common Stock
Cooley has advised Vor Biopharma. Paul Hastings LLP has advised J.P. Morgan, Jefferies, Citigroup, and TD Cowen. Vor Biopharma Inc. has announced the pricing of an...